Research and Markets: Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/36eb77/erectile_dysfuncti) has announced the addition of GlobalData 's new report "Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017" to their offering.

“Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017”

Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global Erectile Dysfunction (ED) therapeutics market. The report identifies the key trends shaping and driving the ED market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ED therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The ED market is currently very competitive and is expected to become more competitive in the future. The market is dominated by three major cyclic Guanosine Monophosphate (cGMP)-specific Phosphodiesterase type 5 (PDE5 inhibitors) including Viagra (sildenafil citrate), Cialis (tadalafil) and Levitra (vardenafil HCl). The market is expected to witness a decline between 2011 and 2014 due to patent expiry of the blockbuster drug Viagra. Viagras patent expires in early 2012 and the market is expected to decline due to erosions of margins with the entry of generics. Post 2014, the market is expected to grow due to an increase in the number of ED patients. GlobalDatas analysis revealed that the market grew at a CAGR of 9.8% from 2001 to 2009. The growth rate was moderate due lack of ED awareness and reluctance among the male general population to discuss their sexual problems. With the patent expiry of Viagra in 2012, the market is expected to decline after 2011, with a CAGR of 3.2% from 2009 to 2017. The analysis showed that the ED pipeline is weak. The products in the ED pipeline comprise of me-too molecules. Some of the promising me-too class drugs/molecules are in Phase III trials and are likely to get approval in coming years. One of the promising molecules is Avanafil, which is unlikely to have much impact as the market has high competition among similar products and will experience generic erosion after 2012 due to patent expiry of Viagra.

Key Topics Covered:

• 1 Contents
• 2 Erectile Dysfunction: Introduction
• 3 Erectile Dysfunction: Market Characterization
• 4 Erectile Dysfunction: Competitive Assessment
• 5 Erectile Dysfunction: Pipeline Assessment
• 6 Erectile Dysfunction Market: Implications for Future Market Competition
• 7 Erectile Dysfunction Market: Future Players in the Erectile Dysfunction Market
• 8 Erectile Dysfunction: Appendix

Companies Mentioned:

• VIVUS, Inc
• Rexahn Pharmaceuticals, Inc
• Palatin Technologies, Inc

For more information visit http://www.researchandmarkets.com/research/36eb77/erectile_dysfuncti